



**AGENIX LIMITED**  
Level 9 123 Epping Rd  
North Ryde NSW 2113  
Australia  
Tel : (612) 8875 7898  
Fax : (612) 8875 7897  
Website : www.agenix.net


~~SEC#82-5258~~

4 November 2002

82-34639

US Securities and Exchange Commission  
Attn: Filing Desk  
450 Fifth Street N.W.  
Washington DC 20549  
UNITED STATES OF AMERICA

SUPPL



Dear Sir

**Re: Submission Under Rule 12g3-2(b) – Agenix Limited**

We refer to the attached announcement that was made to the Australian Stock Exchange. We are providing a copy of this announcement by virtue of our requirements under Rule 12g3-2(b).

Yours sincerely,

Jeff Carter  
Chief Financial Officer & Company Secretary

PROCESSED  
DEC 09 2002  
THOMSON  
FINANCIAL

dlw 11/25



**AGENIX**

**AGENIX LIMITED**  
Level 9 123 Epping Road  
North Ryde NSW 2113  
Tel : (612) 8875 7898  
Fax : (612) 8875 7897

## ASX Announcement

### Clinical Reagent Ready for ThromboView® Human Trials

29 October 2002

Brisbane-based biotechnology company Agenix Ltd [ASX:AGX] today announced that it has manufactured sufficient clinical reagent derived from its proprietary humanised monoclonal antibody to complete Phase I human trials of its blood clot imaging project ThromboView®. The trials are scheduled to begin early next year.

The antibody has been manufactured by scientists from Agenix subsidiary Agen in collaboration with the CSIRO Health Sciences and Nutrition Fermentation Group, Melbourne and Radpharm Scientific, Canberra.

The Phase Ia trial will test ThromboView® in a group of healthy volunteers. Doctors will determine the safety of the product, as well as collecting information about how the drug is distributed in the body. In parallel with this trial a second study (Phase Ib) will take place with a group of patients with confirmed DVT. The results will provide further safety data and clinical performance data from patients with the disease.

The ThromboView® technology is designed to improve the diagnosis and treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) through a superior method of blood clot detection.

"The ThromboView® humanised monoclonal antibody is highly specific for the D-dimer protein, a major component of blood clots," said Sue Parry-Jones, ThromboView® Business Unit Manager. "Agen scientists have processed this antibody to produce vials of clinical reagent in a commercially viable form which is stable and easily radiolabelled at the clinical trial site. Once injected into the bloodstream, the radiolabelled antibody locates blood clots, which can then be detected using an imaging camera that is routinely used in major hospitals."

The clinical reagent for the ThromboView® trials is currently undergoing preclinical studies, which should be completed by the end of November. "Preliminary results suggest a smooth transition to human trials," said Ms Parry-Jones.

Data from the manufacturing process, preclinical studies and approved clinical protocols will be submitted to the Therapeutic Goods Administration for final approval by the end of the year.

**For more information contact:**

**Sue Parry-Jones**  
ThromboView Business Unit Manager  
Ph: 0439 885 416

**Don Home**  
CEO Agenix Ltd  
Ph: 0438 500 255

**Agenix Limited [ASX:AGX]** is a listed Australian-based company. It manufactures, distributes and markets human and veterinary diagnostic test kits, over-the-counter pharmaceuticals and infant care products via its fully-owned subsidiaries AGEN Biomedical and Milton Pharmaceuticals. Agenix focuses on developing a horizontally integrated product portfolio to service the needs of the acute phase thrombosis market. Agenix's lead candidate is its high-technology ThromboView® blood clot-imaging project, which uses radiolabelled antibodies to locate blood clots in the body. This could revolutionise the \$US 3 billion annual clot diagnostic imaging market. Last year Agenix reported a pre-tax profit of \$4.2 million, up 11%, on revenue of \$40 million, up 39%. Cash flow from operations, after research and development costs, increased 479% to \$5.7 million. Agenix employs 190 staff and sells its products to more than 50 countries. Agenix employs 190 staff and sells its products to more than 50 countries.

[www.agenix.net](http://www.agenix.net)